Open AccessSwitching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain
Author(s) -
Kai Juhani Kauppinen,
Inka Aho,
Jussi Sutinen
Publication year - 2022
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003245
Subject(s) - tenofovir alafenamide , tenofovir , pharmacology , norovirus , medicine , chemistry , virology , viral load , human immunodeficiency virus (hiv) , virus , antiretroviral therapy
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) increases low-density lipoprotein cholesterol (LDL-C) and body weight. Metabolic effects of the opposite TAF-to-TDF switch are unknown.